KARYOPHARM THERAPEUTICS INC (KPTI)
Health Care · Oncology biopharmaceuticals / targeted cancer therapeutics · NASDAQ
Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in myelofibrosis and endometrial cancer.
What KARYOPHARM THERAPEUTICS INC does
Karyopharm Therapeutics is a biopharmaceutical company focused on developing and commercializing cancer treatments based on XPO1 (nuclear export) inhibition technology. The company's approved product, XPOVIO (selinexor), is currently marketed in the U.S. for multiple myeloma and other hematologic malignancies. Karyopharm is advancing a clinical pipeline including programs in myelofibrosis, endometrial cancer, and additional multiple myeloma indications, while exploring partnerships to expand XPOVIO's global reach.
Themes: XPO1 inhibition / nuclear export inhibitors, Multiple myeloma treatment, Myelofibrosis treatment, Endometrial cancer treatment, Oncology / cancer therapeutics
Fundamentals
- Price$1.96 as of 2026-08-21 close
- Market cap$44M as of 2026-08-21
- 1-year return-67.4% 2025-08-21 close $6.02 → 2026-08-21 close $1.96
- P/En/a negative earnings
- Net margin-129.0% as of 2026-08-24
- Gross margin+96.0% as of 2026-08-24
- ROE-182.4% as of 2026-08-24
- Debt / equity3.78 as of 2026-08-24
- Revenue growth (YoY)+6.3% as of 2026-08-24
- Revenue CAGR (3y)-2.4% SEC XBRL
- Beta0.97 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How KPTI compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How KARYOPHARM THERAPEUTICS INC looks technically
KARYOPHARM THERAPEUTICS INC (KPTI) is trading 73.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 5 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 52, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 24, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 5 trading days ago. It is 82.2% below its highest point of the past year. Trading volume is unusually light — only about 46% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 73.1% below its 200-day average, the long-term trend line — a long-term downtrend | -73.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.76 | $6.76 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.29 | $7.29 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 2.18. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 3 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 5 trading days ago — a "death cross", a bearish long-term signal | 5 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 52, with sellers in control | 52.3 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 24, in oversold territory (below 30) | 24.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.79 to $2.18) — its "stochastic" reading is 44 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 43.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.99 | $10.99 |
|---|---|---|
| From the 52-week high | it is 82.2% below its 52-week high (its highest price of the past year) | -82.2% |
| Above the 52-week low | it is 9.5% above its 52-week low (its lowest price of the past year) | +9.5% |
| Below the 52-week high | it is 82.2% below its highest point of the past year | 82.2% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $731.42 (set on 2014-12-08) | $731.42 |
| Given back of the 52-week move | over the past year its closes ranged ($1.81 to $10.67), and it has recovered essentially none of its fall from last year’s high — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.29 to $7.57. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.7% |
| From the all-time high | it is 99.7% below its all-time high | -99.7% |
| Nearest price level | it is trading 88.0% below a resistance level at $3.69 — a price it turned at three times since 2025-07-11, most recently on 2025-08-11. Since 2024-08-21 it has 0 such levels below the current price and 21 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +88.0% |
| All-time low | its lowest closing price on record is $0.5522 (set on 2025-02-25) | $0.5522 |
| Above the all-time low | it is 254.9% above its all-time low | +254.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4626 between its high and its low — about 23.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4626 |
| Bollinger bands (20-day, ±2σ) | not available for this company yet | n/a |
| Typical daily range (% of price) | its price moves about 23.6% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 23.6% |
| Stretch from the 200-day average | it is trading 11.5 daily ranges below its 200-day average price (73.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 46% of its 30-day average | 0.46× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 13.3% since the prior reading | +13.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.20 toward buy |
Candlestick patterns
1
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.6% |
|---|---|---|
| Open gap | it gapped 3.9% above the previous close 3 sessions ago and has not traded back through the level it left behind at 1.81 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.9% |
| Gap filled | a 2.1% gap up opened on 2026-06-18 has been "filled" 44 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 44 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 77.4 percentage points (the stock lost 75.1% while the market gained 2.3%) | -77.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 78.8 percentage points (the stock lost 75.7% while the market gained 3.1%) | -78.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 90.8 percentage points (the stock lost 79.7% while the market gained 11.1%) | -90.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 87.9 percentage points (the stock lost 67.4% while the market gained 20.5%) | -87.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 78% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 50.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -77.9% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 66% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $5.80 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -66.2% |
|---|
Price levels it has turned at before
KPTI last closed at $1.96 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 21 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.69 | Resistance | 88.0% above the last close | turned there three times · 2025-07-11 to 2025-08-11 |
| $4.09 | Resistance | 108.7% above the last close | turned there twice · 2025-06-02 to 2025-06-23 |
| $5.00 | Resistance | 155.4% above the last close | turned there twice · 2025-11-07 to 2026-03-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $2.18.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.80 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$7.25 range $3.00 – $11.00; median $7.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KPTI
- Consensus EPS estimate-$1.32 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Company is unprofitable with negative net margin of -129% and significant cash burn, raising substantial doubt about ability to continue as a going concern","XPOVIO is the only source of product revenue and commercial success depends heavily on expanding sales in multiple myeloma and achieving clinical approval in additional indications","Clinical pipeline advancement and regulatory approval timelines are uncertain; failure to achieve development milestones in myelofibrosis, endometrial cancer, or other programs would impact future revenue and valuation"]
What changed in the latest 10-Q
AI-assisted comparison of KPTI's 10-Q filed 2026-05-14 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-14) adds reference to 'potential inclusion of selinexor in combination with ruxolitinib in relevant compendia' in forward-looking statements section
- Removed:
- Older filing (2025-11-03) contained disclosure that 'all share amounts and per share amounts have been adjusted to reflect a 1-for-15 reverse split of our common stock' - this statement is absent from newer filing
- Reworded:
- Annual Report reference updated from 'year ended December 31, 2024, as filed with the Securities and Exchange Commission ("SEC") on February 19, 2025' (older) to 'year ended December 31, 2025, as filed with the Securities and Exchange Commission ("SEC") on February 13, 2026' (newer)
- Notes:
- Comparison limited to provided excerpts; full section may contain additional changes not visible in the truncated texts
Risk Factors
- Added:
- Reference to maintaining minimum liquidity of 'the lesser of (i) $10.0 million plus 50% of the net cash proceeds received from certain debt and equity issuances and (ii) $25.0 million' through October 10, 2026 (newer filing)
- Statement that company has 'incurred significant losses since inception' and expects to continue incurring 'significant losses' (emphasized in newer filing's opening to that risk factor)
- Specific mention of company 'may in the future determine to take actions to reduce our spending in the near term, including reductions to our workforce' (newer filing uses forward-looking language)
- Reference to 'the Open Market Sale Agreement with Jefferies LLC' with specific entity name (newer filing)
- Removed:
- Specific reference to 'In October 2025, we completed a series of financing transactions that resulted in the receipt of approximately $36.0 million of gross proceeds' (removed in newer filing)
- Statement that company 'expect our existing cash resources...to fund our existing operations into the second quarter of 2026' (changed in newer filing)
- Reference to completion of 'Phase 3 SENTRY trial beyond top-line results and the Phase 3 XPORT-EC-042 trial' as specific capital needs (removed in newer filing)
- Specific reference to 'As we announced on July 11, 2025, we reduced our workforce by approximately 20%' (removed in newer filing)
- Reference to '2023 Open Market Sale Agreement with Jefferies' (older filing's specific naming)
- Statement about minimum liquidity 'of at least $10.0 million, subject to increase in the event we issue indebtedness for borrowed money or issue capital stock, through October 10, 2026, after which we will be required to maintain liquidity of at least $25.0 million' (revised formula in newer filing)
- Reference to 'given the uncertainty' regarding funding availability (older filing)
- Statement that there is 'no assurance that such additional financing or strategic alternatives will be available on terms acceptable to us, or at all' without additional language (older filing version)
- Reworded:
- Cash position changed from 'As of September 30, 2025, we had approximately $45.9 million in cash, cash equivalents, and investments' to 'As of March 31, 2026, we had approximately $90.9 million in cash and cash equivalents'
- Runway changed from 'into the second quarter of 2026' to 'to late in the third quarter of 2026'
- Loss metric changed from 'Our net loss was $93.8 million for the nine months ended September 30, 2025' to 'Our loss from operations was $26.8 million for the quarter ended March 31, 2026' (different measurement periods and metrics)
- Accumulated deficit changed from 'As of September 30, 2025, we had an accumulated deficit of $1.7 billion' to 'As of March 31, 2026, we had an accumulated deficit of $1.8 billion'
- Language changed from 'combined with the uncertainty' to 'combined with the uncertainty' (older: 'given the uncertainty') regarding funding availability
- Statement about spending reductions changed from past tense 'We may determine to take additional actions to reduce our spending' to forward-looking 'We have and may in the future determine to take actions to reduce our spending'
- Expanded language on how company will address going concern doubt to include specific mention of Open Market Sale Agreement and data reporting from ongoing Phase 3 trials
- Added clarification that additional financing 'if consummated, will be sufficient to address doubt regarding our ability to continue as a going concern' (newer filing)
- Notes:
- Text from older filing appears truncated at 'An' suggesting comparison may be incomplete at the very end
- Newer filing text also appears truncated at 'Antengene' at end of visible section
- Comparison is limited to the provided text sections and may not capture full context of complete risk factors
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($1342) — 1 selling insider
- Last 90 days0 buys · 1 sell ($1342) — 1 selling insider
- Last 180 days0 buys · 8 sells ($40097) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-28. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KPTI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding KPTI as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 939,220
- Reported value $5,231,455
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
KPTI had 7,555,693 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
KPTI had 33.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.67 days to cover at the same settlement.
- Reported short interest (shares) 7,555,693
- Short interest (% of shares outstanding) 33.3%
- Prior settlement (shares) 6,312,305
- Reported change 19.7%
- Days to cover (reported) 2.67
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Takeda Pharmaceutical (TAK) — multiple myeloma treatments
- Bristol Myers Squibb (BMY) — oncology and multiple myeloma portfolio
- Celgene (acquired by Bristol Myers Squibb) — multiple myeloma therapies
- Novartis (NVS) — oncology and hematology treatments
- Acceleron Pharma / Merck (MRK) — myelofibrosis treatments (luspatercept, fedratinib)
- Genmab (GMAB) — cancer immunotherapy
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KPTI vs…
KPTI ranks in…
Frequently asked questions
What does KARYOPHARM THERAPEUTICS INC (KPTI) do?
Karyopharm Therapeutics is a biopharmaceutical company focused on developing and commercializing cancer treatments based on XPO1 (nuclear export) inhibition technology. The company's approved product, XPOVIO (selinexor), is currently marketed in the U.S. for multiple myeloma and other hematologic malignancies.
What sector is KARYOPHARM THERAPEUTICS INC (KPTI) in?
KARYOPHARM THERAPEUTICS INC (KPTI) is classified in the Health Care sector. Its industry is Oncology biopharmaceuticals / targeted cancer therapeutics. It trades on NASDAQ.
Who are KARYOPHARM THERAPEUTICS INC's (KPTI) competitors?
Notable peers of KARYOPHARM THERAPEUTICS INC (KPTI) include Takeda Pharmaceutical (TAK) — multiple myeloma treatments, Bristol Myers Squibb (BMY) — oncology and multiple myeloma portfolio, Celgene (acquired by Bristol Myers Squibb) — multiple myeloma therapies, Novartis (NVS) — oncology and hematology treatments and Acceleron Pharma / Merck (MRK) — myelofibrosis treatments (luspatercept, fedratinib). This peer set is informational only — not financial advice.
Is KARYOPHARM THERAPEUTICS INC (KPTI) overbought or oversold right now?
KARYOPHARM THERAPEUTICS INC (KPTI) is currently in oversold territory (its 14-day RSI is 24, below 30) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KPTI come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.